Effect of BI 1815368 on Metformin PK

Phase 1, randomised, open-label trial of BI 1815368 in diabetic macular edema (DME) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval tau and Maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval tau. Started Nov 2024; status: completed.